COX-1 sparing and COX-2 inhibitory drugs: The renal and hepatic safety and tolerability profiles of celecoxib

American Journal of Therapeutics

Volumn 7, Issue 3, 2000, Pages 151-152

  Whelton, Andrew ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Universal Clinical Research Center Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

DRUG EFFECT; HUMAN; KIDNEY; LIVER; METABOLISM; NOTE; PHYSIOLOGY;

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; KIDNEY; LIVER; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0034189702     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200007030-00002     Document Type: Article

References (26)

1. Fletcher BS, Kujubu DA, Perin DM, Herschman HR: Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;293: 4338-4344.
2. Masferrer JL, Isaakson PC, Seibert K: Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996;25:363-372.
3. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J Biol Chem 1996;271:33157-33160.
4. Herschman HR: Prostaglandin synthase 2. Biochem Biophys Acta 1996;1299:125-140.
5. Vane JR, Botting RM: Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997;26:2-10.
6. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
7. Khan KNM, Venturini CM, Bunch RT, et al: Interspecies differences in renal location of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxidty. Toxicol Pathol 1998;26:612-620.
8. Eberhart CE, Dubois RN: Eicosanoids and the gastrointestinal tract. Gastroenterology 1995;109:285-301.
9. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;3430:1888-1899.
10. Funk CD, Funk LB, Kennedy ME, et al: Human platelet/ erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1988;5:2304-2312.
11. Whelton A: Nephrotoxicity of nonsteroidal antiinflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106(5B):13S-24S.
12. Seibert K, Zhang Y, Leahy K, et al: Pharmacologic and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-12017.
13. Kang RY, Freire-Moar J, Sigal E, et al: Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711-718
14. Zhang Y, Shaffer A, Portanova J, et al: Inhibition of cycIooxygenase-2 rapidly reverses inflammatory hyperanalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997;283:1069-1075.
15. Cashman JN. The mechanism of action of NSAIDs in analgesia. Drugs 1996;52(Suppl 5):13-23.
16. Harris RC, McKanna JA, Akai Y, et al: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
17. Breitner JCS: Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 1996;17:789-794.
18. Kaufman WE, Worley PF, Pegg J, et al: COX-2 a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 1996;93:2317-2321.
19. Chakraborty I, Das SK, Wang J, et al: Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996;16:107-122.
20. Kawaguchi H, Pilbeam CC, Harrison JR, et al: The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 1995;313:36-46.
21. Lipsky PE, Abramson SB, Crofford L, et al: The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25:2298-2303.
22. Simon LS, Lanza FL, Lipsky PE, et al: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998;41:1519-1602.
23. Ehrich EW, Schnitzer TJ, McLiwain H, et al: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6- week double-blind, placebo-controlled pilot study of rofecoxib. J Rheumatol 2000, in press.
24. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-484.
25. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A metaanalysis. Ann Intern Med 1994;212:289-300.
26. Heerdink ER, Leufkens HG, Herings RMC, et al: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-1112.